Why is Stereotaxis stock sliding today?
Stereotaxis (STXS) fell 14.6% after Q3 2026 results missed estimates, with a $0.07 adjusted loss per share and $8.9M revenue. Supply shortages of MAGiC catheters and a $24M convertible note financing at $1.21/share raised concerns. TD Cowen cut its price target to $2.00. The stock hit a 52-week low of $0.80.
How this was made
The 30-second read
Why it matters
The earnings miss and dilutive financing triggered a sharp intraday sell‑off, highlighting near‑term profitability concerns.
Market read
STXS's stock fell 14.6% on earnings miss and financing news, contrasting with broader market gains.
What to watch
Potential upside from future catheter supply improvements and cash‑flow from the convertible note.
Background
STXS reported a Q3 loss of $0.07 per share versus a $0.05 expected loss, with revenue $8.9M versus $9.9M forecast.
Ticker impact
Q3 2026 earnings miss and dilutive convertible note financing drove a 14.6% drop to $0.80.
downward pressure as investors price in missed estimates and dilution.
Both revenue and EPS missed expectations; convertible note adds dilution risk.
Market effects
Medical robotics sector may see relative outperformance as STXS underperforms.
U.S. small‑cap biotech/medical device segment faces heightened volatility.
Limited; impact confined to U.S. equity markets.
Counterpoint
The price dip may present a short‑term buying opportunity if the backlog resolves.
Key entities
- companyStereotaxis
Medical robotics firm reporting Q3 results.
- contract manufacturerOsypka
Supplier of MAGiC catheters experiencing shipment shortfall.


